Filtered By:
Therapy: Gene Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 5568 results found since Jan 2013.

Multiscale modeling of the cellular uptake of C6 peptide-siRNA complexes
In this study, multiscaled computational simulations of these peptides were performed in aqueous media, interrogating the relationship between the structure and behaviour. All atom molecular dynamic (MD) simulation results show that all CPPs show stable α-helical amphipathic secondary structures. Furthermore, docking calculations indicate that the C6 peptides can fit into the major groove of the siRNA double-helix, and once filled, could bind randomly along the minor grooves and to other, previously bound peptides. Coarse grained MD simulations were also used to generate free energy profiles for the dimerization of peptid...
Source: Computational Biology and Chemistry - April 24, 2022 Category: Bioinformatics Authors: P W C M Purijjala P V G M Rathnayake B T Kumara B C M Gunathunge R A A P Ranasinghe D N Karunaratne R J K U Ranatunga Source Type: research

Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
The objective of this work consists in formulating and optimizing the encapsulation of siRNA into lipid nanocapsules (LNCs) for efficient gene therapy on melanoma cells. SiRNA LNCs were prepared from DOTAP/DOPE lipoplexes, and the siRNA dose and lipid/siRNA charge ratio were assayed to improve the stability and encapsulation yield. Cryo-TEM imaging of the siRNA lipoplexes and LNC morphology revealed a specific organization of the siRNA DOTAP/DOPE lipoplexes as well as specific lipid microstructures. No cytotoxicity of the siRNA LNCs against the melanoma SK-Mel28 cell line was observed at concentrations of up to 500 ng/mL s...
Source: Biotechnology Journal - September 26, 2014 Category: Biotechnology Authors: Resnier P, LeQuinio P, Lautram N, André E, Gaillard C, Bastiat G, Benoit JP, Passirani C Tags: Biotechnol J Source Type: research

Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
In this study, we constructed novel oncolytic adenoviruses in which the Ki67 core promoter drove expression of the E1A gene. These adenoviruses were equipped with either a Ki67 small interfering RNA (siRNA), a human telomerase reverse transcriptase (hTERT) siRNA or a double siRNA targeting Ki67 and hTERT. We identified the antitumor activities of oncolytic adenoviruses in 3 renal cancer cell lines, human normal renal tube cell HK-2 and also in nude mice bearing KETR-3-xenografted tumors. Our results showed that these oncolytic adenoviruses, especially Ki67-ZXC2-double siRNA, could effectively induce silencing of the Ki67 a...
Source: Virus Research - January 21, 2014 Category: Virology Authors: Fang L, Cheng Q, Li W, Liu J, Li L, Xu K, Zheng J Tags: Virus Res Source Type: research

Lentivirus vectors construction of SiRNA targeting interference GPC3 gene and its biological effects on liver cancer cell lines Huh-7
Conclusions The targeted GPC3 siRNA can effectively inhibit the expression of GPC3.
Source: Asian Pacific Journal of Tropical Medicine - October 12, 2014 Category: Tropical Medicine Source Type: research

Glycyrrhetinic acid-modified graphene oxide mediated siRNA delivery for enhanced liver-cancer targeting therapy.
Abstract Graphene oxide (GO) has attracted huge attention in biomedical field in recent years. However, limited attempts have been invested in utilizing GO on active targeted delivery for gene therapy in liver cancer treatments. Glycyrrhetinic acid (GA) has been reported to be widely used as a targeting ligand to functionalize nanomaterials to treat hepatocellular carcinoma. In this article, GA is employed as a liver targeting ligand to construct GA, polyethylene glycol (PEG), polyamidoamine dendrimer (Dendrimer) and nano-graphene oxide (NGO) conjugate (GA-PEG-NGO-Dendrimer, GPND) for siRNA delivery for the first ...
Source: European Journal of Pharmaceutical Sciences - August 21, 2019 Category: Drugs & Pharmacology Authors: Qu Y, Sun F, He F, Yu C, Lv J, Zhang Q, Liang D, Yu C, Wang J, Zhang X, Xu A, Wu J Tags: Eur J Pharm Sci Source Type: research

Preclinical development of siRNA therapeutics: Towards the match between fundamental science and engineered systems
Abstract: The evolution of synthetic RNAi faces the paradox of interfering with the human biological environment. Due to the fact that all cell physiological processes can be target candidates, silencing a precise biological pathway could be challenging if target selectivity is not properly addressed. Molecular biology has provided scientific tools to suppress some of the most critical issues in gene therapy, while setting the standards for siRNA clinical application. However, the protein down-regulation through the mRNA silencing is intimately related to the sequence-specific siRNA ability to interact accurately with the ...
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - December 11, 2013 Category: Nanotechnology Authors: M. Videira, A. Arranja, D. Rafael, R. Gaspar Tags: Cell Biology and Genetics, Amino Acids, Nucleic Acids, siRNA Therapy, Basic Science vs. Engineering Source Type: research

Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells
& H Uludağ
Source: Cancer Gene Therapy - March 1, 2013 Category: Cancer & Oncology Authors: H M AliabadiP MahdipoorH Uludağ Tags: lipophilic polymers Mcl-1 multidrug resistance P-glycoprotein siRNA delivery Source Type: research

Nanostructured Hyaluronic acid-based materials for the delivery of siRNA.
CONCLUSION: To overcome the problems associated with these emerging genetic tools, investigators have employed glycosaminoglycan HA-based biopolymers. This biopolymer offers a variety of properties such as biodegradability, biocompatibility, aqueous solubility, viscoelasticity, and non-immunogenicity. PMID: 30084325 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 7, 2018 Category: Drugs & Pharmacology Authors: Shah K, Chawla S, Agrawal A, Reddy G, Maheshwari R, Kalia K, Tekade RK Tags: Curr Pharm Des Source Type: research

Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211041453. doi: 10.1177/15330338211041453.ABSTRACTDelivery of small-interfering RNA (siRNA) has been of great interest in the past decade for effective gene silencing. To overcome synthetic and regulatory challenges posed by nanoparticle-mediated siRNA delivery, antibody-siRNA conjugate (ARC) platform is emerging as a potential siRNA delivery system suitable for clinical translation. Herein, we have developed a delivery technology based on the ARC platform for stable delivery of siRNA called as Gelatin-Antibody Delivery System (GADS). In GADS, positively charged gelatin act...
Source: Cell Research - September 20, 2021 Category: Cytology Authors: K Sreedurgalakshmi R Srikar K Harikrishnan Lakshmi Srinivasan Reena Rajkumari Source Type: research

Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy
Life Sci. 2022 Mar 5:120463. doi: 10.1016/j.lfs.2022.120463. Online ahead of print.ABSTRACTGene therapy can be used as a cancer therapy by affecting signaling networks participating in the aggressive behavior of tumors. Small interfering RNA (siRNA) is a genetic tool employed for gene silencing. The siRNA molecules have a length of 21-22 nucleotides, and are synthetic, short non-coding RNAs. The siRNA molecule should be loaded into the RISC complex to carry out its function to degrade mRNA and reduce protein expression. By targeting oncogenic pathways, siRNA can also promote chemosensitivity and reduce resistance. Doxorubi...
Source: Cancer Control - March 8, 2022 Category: Cancer & Oncology Authors: Mahshid Deldar Abad Paskeh Hamidreza Saebfar Mahmood Khaksary Mahabady Sima Orouei Kiavash Hushmandi Maliheh Entezari Mehrdad Hashemi Amir Reza Aref Michael R Hamblin Hui Li Ang Alan Prem Kumar Ali Zarrabi Saeed Samarghandian Source Type: research

Clinical pharmacology of siRNA therapeutics: current status and future prospects
Expert Rev Clin Pharmacol. 2022 Oct 17. doi: 10.1080/17512433.2022.2136166. Online ahead of print.ABSTRACTINTRODUCTION: Small interfering RNA (siRNA) has emerged as a powerful tool for post-transcriptional downregulation of multiple genes for various therapies. Naked siRNA molecules are surrounded by several barriers that tackle their optimum delivery to target tissues such as limited cellular uptake, short circulation time, degradation by endonucleases, glomerular filtration, and capturing by the reticuloendothelial system (RES).AREAS COVERED: This review provides insights into studies that investigate various siRNA-based...
Source: Cell Research - October 17, 2022 Category: Cytology Authors: Ahmed Khaled Abosalha Jacqueline Boyajian Waqar Ahmad Paromita Islam Merry Ghebretatios Sabrina Schaly Rahul Thareja Karan Arora Satya Prakash Source Type: research